EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Star Sports Medicine Co., Ltd. (1609) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Star Sports Medicine Co., Ltd. HK$108, price HK$101, upside +6.2%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · HK

SS Some data Sep 24, 2026

Star Sports Medicine Co., Ltd.

1609 · HK

NeutralQuality growthThe stock looks roughly fairly valued with average quality.

·Fair value HK$107.50 · Fairly valued (+6%)
✓Quality 74/100
✓Healthy Growth (revenue 3y +40.1 %/yr)
✓Highly profitable · 34.0% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (7/13)
✓Wide moat 72/100
!Evidence only medium, so the estimate is less certain
Watch Star Sports Medicine Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$218.40 HK$100.00 Fair Value HK$107.50 May 2026 Sep 2026

White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.

How to read this chart

5‑month range HK$100.00 – HK$218.40 · fair‑value band HK$66.26 – HK$171.98 · the HK$101.20 price screens below the HK$107.50 fair value. As of Sep 24, 2026.

Follow Star Sports Medicine Co. in your weekly email

Every Wednesday you see whether Star Sports Medicine Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China.

Show more

Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon fiber reinforced PEEK suture anchor; interference screws and sheath fixation system, bioabsorbable interference screw, bioabsorbable interference screws and sheath fixation system, PEEK screws and sheath fixation system, and PEEK composite interference screw; suture buttons and high-strength sutures, such as adjustable suture button, fixed suture button, ultra-high molecular weight polyethylene(UHMWPE) suture; meniscus repair systems, all-suture meniscus repair system, accurFix all-inside meniscus repair system, and multi-needle and flexible meniscus repair system. The surgical equipment and associated medical consumables, includes plasma RF ablation equipment, arthroscopic surgical shaver, arthroscopic camera system, and disposable shaver blade plasma electrode. Its other products includes disposable PRP preparation kit, desktop centrifuge. The company also provides biomaterial platform, imaging and dynamic platform, intelligent medicine platform, and tissue engineering platform. The company was founded in 2017 and is headquartered in Beijing, China.

Stock analysis

Star Sports Medicine Co., Ltd. (1609) currently trades at HK$101.20, while our model-based Fair Value estimate is HK$107.50, implying the stock looks roughly 5.9% fairly valued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$102.09 per share, and 2 of the 24 models we run sit above the HK$101.20 price.

Bear case: the Economic Profit group reads lowest at HK$19.16, and 22 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: HK$66.26 (bear) to HK$171.98 (bull), the price of HK$101.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Star Sports Medicine Co., Ltd. reported revenue of 403M CNY in FY2025 versus 147M CNY in FY2022, a compound +40.1%/yr. Reported net income was 137M CNY in FY2025, compounding +50.3%/yr from FY2022.

Key figures

Market cap HK$8.5B (≈ $1.1B) · P/E ratio 53.8 · P/S ratio 18.3 · Net margin 34.0% · Return on equity 25.4% · Return on assets (EBIT) 15.3% · Operating margin 7.5% · Revenue (TTM) 403M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 6%, 1609 screens cheaper than that median.

Fair Value models

Bear HK$66.26 Fair Value HK$107.50 Bull HK$171.98
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF HK$32.36 HK$46.42 HK$88.43 74
Growth DCF HK$30.43 HK$51.29 HK$84.08 73
EPV HK$20.63 HK$23.20 HK$25.35 71
All 24 models by family
DCF Models
FCF DCF HK$32.36 HK$46.42 HK$88.43 74
Owner Earnings HK$29.18 HK$58.56 HK$113.07 69
5Y Revenue Exit HK$18.45 HK$27.15 HK$45.08 68
5Y EBITDA Exit HK$33.50 HK$57.55 HK$104.67 69
5Y P/E Exit HK$38.77 HK$84.88 HK$147.76 65
10Y Revenue Exit HK$22.89 HK$39.93 HK$48.35 65
10Y EBITDA Exit HK$33.28 HK$69.48 HK$131.91 62
10Y P/E Exit HK$36.79 HK$79.83 HK$150.57 58
Earnings-Based
Graham-Dodd HK$16.99 HK$118.46 HK$166.24 60
Lynch FV HK$53.16 HK$75.94 HK$98.72 58
PEG = 1.0 HK$53.16 HK$75.94 HK$98.72 55
EPV HK$20.63 HK$23.20 HK$25.35 71
Multiples
P/E Multiple HK$39.34 HK$52.46 HK$65.57 63
P/S Multiple HK$11.02 HK$14.69 HK$18.36 58
P/B Multiple HK$31.85 HK$42.47 HK$53.08 55
EV/EBIT HK$39.81 HK$52.48 HK$65.15 66
EV/EBITDA HK$33.50 HK$44.07 HK$54.64 67
EV/Revenue HK$11.04 HK$15.01 HK$18.98 54
Asset-Based
NCAV (Graham) HK$5.56 HK$7.45 HK$11.11 54
Growth DCF
Growth DCF HK$30.43 HK$51.29 HK$84.08 73
Rev-Margin DCF HK$19.43 HK$30.84 HK$53.83 67
Economic Profit
Residual Income HK$14.30 HK$19.16 HK$75.56 55
ROIC Compounder HK$26.18 HK$38.06 HK$46.69 69
Growth Earnings
Growth-Adj P/E HK$71.46 HK$102.09 HK$132.71 65

Open the full fair value analysis →

Notify me when 1609 reaches fair value

Put 1609 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 74/100

Of which business quality 75 · Market factors (momentum, volatility) 4

Profitability 76
Margins and returns on capital today
Quality Growth 78
Are margins and returns improving?
Cashflow 79
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 21
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 9
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+23.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.1%
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+52.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+52.0%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 41%
2025 sits 140% above its own trend. The rate follows the median trend of the last 3 years, not that single year.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +25.1% a year for the price.

Watch 1609, get fair value alerts →

Compare Star Sports Medicine Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 74 · Top 25%
Fair Value upside +6% · Above median
Profitability
Return on equity (TTM) 25% · Top 25%
Return on assets 12% · Top 25%
Net margin (TTM) 34% · Top 25%
Operating margin (TTM) 8% · Above median
Growth and dividend
Revenue growth 0% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 53.8× · Priciest 25%
P/B 11.92× · Priciest 25%
P/S (TTM) 18.04× · Priciest 25%
P/FCF 8.8× · Pricier than median
EV/EBITDA 50.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)42 · sector 10
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)100 · sector 7
HEALTH (low debt)98 · sector 97
DIVIDEND (yield)0 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Medtronic plc MDT $89.30 $65.57 −27%
Stryker Corporation SYK $269.75 $296.73 +10%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Star Sports Medicine Co., Ltd. · Fair Value
HK$107.50 +6%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Star Sports Medicine Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/1609

Frequently asked questions

Is Star Sports Medicine Co., Ltd. (1609) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$107.50 versus a price of HK$101.20, about +6% upside (fairly valued).
What is the fair value of 1609?
Our model-based fair value for Star Sports Medicine Co., Ltd. is HK$107.50 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$101.20.
What is the quality score of 1609?
Star Sports Medicine Co., Ltd. has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Star Sports Medicine Co., Ltd. (1609)?
Our model-based price target is the fair value of HK$107.50 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario HK$66.26, optimistic scenario HK$171.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Star Sports Medicine Co., Ltd. stock forecast for 2026?
Our models put fair value at HK$107.50, about +6% upside versus a price of HK$101.20 (fairly valued). Cautious scenario HK$66.26, optimistic scenario HK$171.98. The calculation is refreshed regularly with new filings.
What is the revenue of Star Sports Medicine Co., Ltd. (1609)?
Star Sports Medicine Co., Ltd. reported trailing-twelve-month revenue of about 403M CNY (latest available figure, as of Sep 24, 2026).
What growth is priced into Star Sports Medicine Co., Ltd. (1609)?
For today's price to be fair in a discounted-cash-flow model, Star Sports Medicine Co., Ltd. would have to grow free cash flow by +27.2 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +40.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1609 use?
Our models discount Star Sports Medicine Co., Ltd. at 11.8 %: a base by market capitalisation (small), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Star Sports Medicine Co., Ltd. that is +27.2 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Star Sports Medicine Co., Ltd. (1609) delivered so far?
Over the past 3 years revenue at Star Sports Medicine Co., Ltd. grew +40.1 % a year. The price currently implies +27.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Star Sports Medicine Co., Ltd. (1609) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Star Sports Medicine Co., Ltd. (+27.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Star Sports Medicine Co., Ltd. (1609)?
The free-cash-flow yield on the price is 2.59 %: that much free cash flow Star Sports Medicine Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Star Sports Medicine Co., Ltd. (1609)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Star Sports Medicine Co., Ltd. it is HK$107.50 per share (as of Sep 24, 2026), against a price of HK$101.20. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Star Sports Medicine Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1609 trades below its calculated fair value: price HK$101.20, fair value HK$107.50, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1609?
No. The price is what the market pays today (HK$101.20); the fair value is what the company's own numbers justify (HK$107.50). For Star Sports Medicine Co., Ltd. the two are HK$6.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Star Sports Medicine Co., Ltd. worth?
The market values Star Sports Medicine Co., Ltd. at about HK$8.5B (market capitalisation, as of Sep 24, 2026). Per share that is HK$101.20; our models calculate a fair value of HK$107.50 per share.
What do the bullish and bearish scenarios say about 1609?
Our models span a range for Star Sports Medicine Co., Ltd.: cautious scenario HK$66.26, base HK$107.50, optimistic HK$171.98 per share (as of Sep 24, 2026, price HK$101.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1609?
Star Sports Medicine Co., Ltd. trades at a price-to-earnings ratio of 53.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$107.50 is built from several models across several years. Other multiples: P/B 11.9, P/S 18.0, EV/EBITDA 50.0.
How solid is the balance sheet of Star Sports Medicine Co., Ltd. (1609)?
Balance-sheet figures for Star Sports Medicine Co., Ltd. (as of Sep 24, 2026): return on equity 25.4%, debt of 0.03 per unit of equity. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
Which stocks are comparable to Star Sports Medicine Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Star Sports Medicine Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price HK$101.20, calculated fair value HK$107.50 (+6%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1609 calculated?
We run Star Sports Medicine Co., Ltd. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$107.50, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Star Sports Medicine Co., Ltd. currently trades 6 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Star Sports Medicine Co., Ltd. (1609)?
The closing price on Sep 24, 2026 was HK$101.20. Our model-based fair value is HK$107.50, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Star Sports Medicine Co., Ltd. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$66.26 to HK$171.98) leaves room in how you read the outcome.

Key figures of Star Sports Medicine Co., Ltd.

How large is the market capitalisation of Star Sports Medicine Co., Ltd. (1609)?
The market capitalisation of Star Sports Medicine Co., Ltd. is HK$8.5B (≈ $1.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Star Sports Medicine Co., Ltd. (1609)?
The price-to-sales ratio of Star Sports Medicine Co., Ltd. is 18.3 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Star Sports Medicine Co., Ltd. (1609)?
The net margin of Star Sports Medicine Co., Ltd. is 34.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Star Sports Medicine Co., Ltd. (1609)?
The return on equity (ROE) of Star Sports Medicine Co., Ltd. is 25.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Star Sports Medicine Co., Ltd. (1609)?
On an EBIT basis the return on assets of Star Sports Medicine Co., Ltd. is 15.3% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Star Sports Medicine Co., Ltd. (1609)?
The operating margin of Star Sports Medicine Co., Ltd. is 7.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
Free · no account needed

Watch Star Sports Medicine Co., Ltd. in the live analysis

One click puts Star Sports Medicine Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.